OPM-201 / Oncodesign - LARVOL DELTA

Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers (Businesswire) - "Oncodesign Precision Medicine...today announces the reacquisition of the rights to its OPM-201 program in the treatment of Parkinson’s disease from Servier laboratories...Final Phase 1 results are expected in the second quarter of 2025. After 5 years of collaboration with Servier, OPM is taking over the development of the program internally, following a strategic decision by Servier laboratories to refocus its Neurology efforts on rare diseases."

Commercial • P1 data • CNS Disorders • Parkinson's Disease

OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation (Businesswire) - "OPM-101 successfully completed its Phase 1 trial with healthy volunteers, enabling the company to anticipate the start of a Phase 1b/2a clinical trial in 2024/early 2025...OPM-201, licensed to Servier for the treatment of Parkinson's disease, completed its Phase I trial in healthy volunteers this year, with Phase II scheduled to start in 2025."

New P1/2 trial • New P2 trial • CNS Disorders • Immunology • Inflammatory Bowel Disease • Parkinson's Disease

Servier Exercises the Exclusive Worldwide License Option of Their Collaboration Program With Oncodesign Precision Medicine (OPM) on Parkinson’s disease (Businesswire) - "CTA approval by the ANSM and the EC of the phase 1 program resulting from the collaboration between Servier and Oncodesign Precision Medicine for the development of an innovative treatment in Parkinson's disease...Servier...and Oncodesign Precision Medicine...announce that Servier has exercised its exclusive license option for their drug candidate, an inhibitor of the LRRK2 (Leucine-Rich-Repeat Kinase 2) kinase target....Servier expects to start a 'Phase 1 study in healthy volunteers' before the end of 2022. The exercise of the option triggers a €7 million milestone payment by Servier to OPM. In total, Servier could pay OPM up to €320 million in R&D, regulatory and commercial milestones, plus potential royalties on future sales."

Licensing / partnership • New P1 trial • CNS Disorders • Parkinson's Disease